Rheumatology Research Workshop 2018

Format:

live

Start Date:

06/23/2018

End Date:

06/24/2018

Location:

San Francisco, CA

Max Credits:

0.00

Credit Type:

Program Information

This two-day Rheumatology Research Workshop (RRW) is designed to promote interactions between young and established investigators to foster collaboration and career mentoring. The meeting includes scientific lectures, oral abstract presentations, poster sessions, and scheduled time for interaction with senior investigators attending the Rheumatology Research Foundation's Investigators Meeting. Attendees are encouraged to also exchange ideas with other trainees and early career investigators.

 

Application

Abstract submission is closed.

 

Target Audience

  • Medical students or residents enrolled in an ACGME-accredited pediatric, medicine, or combined medicine/pediatric residency program
  • Graduate students in a doctoral program who are interested in rheumatology
  • Fellows-in-training at ACGME-accredited program in rheumatology or pediatric rheumatology
  • Junior faculty members within six years of completing his/her fellowship training program

Travel Award

ACR offers travel award scholarships to accepted participants up to $500 for accommodation and travel expenses. Awardees are encouraged to seek matching funds from their institution.

A letter of support is required from your Division Chief, Program Director, or Research Supervisor to supplement the ACR travel award.

Travel Award Criteria

  • Abstract submissions from the previous year's ACR/ARHP Annual Meeting are allowed
  • Abstract submission and acceptance is required for all meeting attendees
  • Abstracts submitted will be used as the basis for awarding the scholarship and potential of the applicant to benefit from the RRW
  • Abstracts submitted to the RRW are eligible to be submitted to the upcoming ACR/ARHP Annual Meeting, as long as it has not been accepted for publication as a manuscript at the time of the ACR/ARHP Annual Meeting submission deadline
  • Only one abstract submission allowed per applicant
  • Applicants should be the lead author on the submitted abstract

Please note, participation of early investigators performing research but without completed studies is encouraged. Abstracts can therefore contain study/design protocols (prior to data collection), research in progress, or preliminary results in addition to completed studies.

Abstract Format

The abstract limit is 2,750 characters, excluding authors and affiliations, spacing, or disclosures. In addition, if you include tables or figures (maximum tables/figures of 2), your character count will decrease by 250 characters from the total limit allowed. Abstract title and author(s) do not count toward the 2,750 character limit.

Your abstract will be considered “incomplete” and not reviewed if the character limit is exceeded or other directions are not followed.

Title
Titles should be brief, clearly indicating the nature of the presentation. When entering your title online, use mixed case (do not use all caps), and do not put a period at the end of the title. Do not enter the title in the body of the abstract.

Example: This is a Properly Formatted Abstract Title

Authors
You may list no more than 25 individual authors for each abstract.  In addition to the 25 authors, an authoring group may be listed to indicate the remaining authors.

Content
Omit all names and geographical references in the body of the abstract. Organize content as follows:

  • Background or Statement of Purpose
  • Methods, materials, and analytical procedure used
  • Summary of the results in sufficient detail to support conclusion. (For abstracts detailing study design abstracts or research-in-progress, anticipated results or hypothesis to be tested are acceptable.)
  • Conclusions reached. (For abstracts detailing study design or research-in-progress, significance and implications are acceptable.)

Use of Product Names
The non-proprietary (generic/scientific) name can be used in the abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract. Failure to follow this rule will result in disqualification of the submission.

Abbreviations
Use standard abbreviations. Place special or unusual abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.

Tables and Graphics
Specific information regarding acceptable graphic files is included in the online submission program. PowerPoint files are not accepted. A maximum of two tables or figures is allowed (see additional abstract details above).

Abstract Eligibility

  • Abstracts describing original basic and clinical work related to the broad area of rheumatic diseases may be submitted.
  • Abstracts detailing study design protocols, research-in-progress, and preliminary results are eligible for consideration.
  • An abstract is ineligible for consideration if it reports work that has been accepted for publication as a manuscript prior to the ACR submission deadline.
  • The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
  • Case reports are not considered appropriate and will not be reviewed.
  • If the abstract reports results of a clinical trial not yet approved by a regulatory agency, the presenting author will be required to identify the trial phase.
  • Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

Abstract Submission

Abstracts must be submitted online at the time of application submission. Before starting the online application, please read these instructions:

  • All files must be in MS Word format and saved as ".doc" or .docx files
  • Use one inch margins, Arial font and 11-point font size (does not apply to figures and tables)
  • The header of each page must contain the applicant's last name and first initial (formatted as last name, first initial)
  • Filenames should be named applicants last name (e.g., "Smith") and must not exceed 15 characters in length

Abstract Review Process

After the submission deadline, all complete abstracts in the system will be sent for review. Any abstracts left “incomplete” will not reviewed.

  • Accepted abstracts will be presented at the poster session. The Early Career Investigators Subcommittee will determine the format based on the abstract topic and the relationship to others in the review categories
  • ACR will notify all applicants of their status in February 2018

Physician Payment Sunshine Act

The Rheumatology Research Workshop scholarship is funded through the 2018 Fellows Education Fund.

Under the Physician Payment Sunshine Act (the "Act"), passed as Section 6002 of the Patient Protection and Affordable Care Act of 2010, the Rheumatology Research Workshop scholarship is a reportable payment to physicians, made indirectly through the ACR. The supporting companies of the fund may require information from the ACR in order to fulfill reporting obligations to the Centers for Medicare and Medicaid ("CMS") for supporting the 2018 Fellows Education Fund, which includes the following information for each scholarship recipient:

  • NPI
  • Name
  • Institution
  • Address
  • Amount of funding provided

ACR is not responsible for, nor has control over, the contents of the report by supporting companies made to CMS, but we encourage you to seek additional information of the scope and contents of such reporting from the CMS website.